17 results on '"Summa, Maria"'
Search Results
2. Electrosprayed zein nanoparticles as antibacterial and anti-thrombotic coatings for ureteral stents
- Author
-
Lenzuni, Martina, Fiorentini, Fabrizio, Summa, Maria, Bertorelli, Rosalia, Suarato, Giulia, Perotto, Giovanni, and Athanassiou, Athanassia
- Published
- 2024
- Full Text
- View/download PDF
3. Electrospun polyvinylpyrrolidone (PVP) hydrogels containing hydroxycinnamic acid derivatives as potential wound dressings
- Author
-
Contardi, Marco, Kossyvaki, Despoina, Picone, Pasquale, Summa, Maria, Guo, Xiao, Heredia-Guerrero, José Alejandro, Giacomazza, Daniela, Carzino, Riccardo, Goldoni, Luca, Scoponi, Giulia, Rancan, Fiorenza, Bertorelli, Rosalia, Di Carlo, Marta, Athanassiou, Athanassia, and Bayer, Ilker S.
- Published
- 2021
- Full Text
- View/download PDF
4. Engineering shape-defined PLGA microPlates for the sustained release of anti-inflammatory molecules
- Author
-
Di Francesco, Martina, Primavera, Rosita, Summa, Maria, Pannuzzo, Martina, Di Francesco, Valentina, Di Mascolo, Daniele, Bertorelli, Rosalia, and Decuzzi, Paolo
- Published
- 2020
- Full Text
- View/download PDF
5. Polyvinylpyrrolidone/hyaluronic acid-based bilayer constructs for sequential delivery of cutaneous antiseptic and antibiotic
- Author
-
Contardi, Marco, Russo, Debora, Suarato, Giulia, Heredia-Guerrero, José A., Ceseracciu, Luca, Penna, Ilaria, Margaroli, Natasha, Summa, Maria, Spanò, Raffaele, Tassistro, Giovanni, Vezzulli, Luigi, Bandiera, Tiziano, Bertorelli, Rosalia, Athanassiou, Athanassia, and Bayer, Ilker S.
- Published
- 2019
- Full Text
- View/download PDF
6. A biocompatible sodium alginate/povidone iodine film enhances wound healing.
- Author
-
Summa, Maria, Russo, Debora, Penna, Ilaria, Margaroli, Natasha, Bayer, Ilker S., Bandiera, Tiziano, Athanassiou, Athanassia, and Bertorelli, Rosalia
- Subjects
- *
WOUND healing , *BIOMEDICAL materials , *SODIUM alginate , *POVIDONE-iodine , *SURGICAL dressings - Abstract
In the last few years, there has been an increasing tendency to use natural polymers for the fabrication of dressings for wound and burn management. Among them, alginate, a polysaccharide extracted primarily from marine algae, exhibits attractive properties being non-toxic, hydrophilic and biodegradable. The aim of this study was to characterize the in vitro biocompatibility and the efficacy of a composite polymeric material based on sodium alginate (NaAlg) and povidone iodine (PVPI) complex in a mouse model of wound healing. The developed material combines the excellent wound healing properties of alginates with the bactericidal and fungicidal properties of PVPI, providing a controlled antiseptic release. We demonstrated that the NaAlg/PVPI films are able to reduce the inflammatory response both in human foreskin fibroblasts after lipopolysaccharide (LPS) stimulus and in rodents after wound induction. Furthermore, the NaAlg/PVPI film-treated animals showed a significantly higher wound closure compared to untreated animals at each time point considered. Interestingly, the complete wound closure was achieved within 12 days only in the film-treated group, indicating that the full-thickness wounds healed more rapidly in these animals. The results demonstrate that the NaAlg/PVPI films are biocompatible and possess healing properties that accelerate the wound closure. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Toolkit for US colleges/schools of pharmacy to prepare learners for careers in academia.
- Author
-
Haines, Seena L., Summa, Maria A., Peeters, Michael J., Dy-Boarman, Eliza A., Boyle, Jaclyn A., Clifford, Kalin M., and Willson, Megan N.
- Abstract
Introduction The objective of this article is to provide an academic toolkit for use by colleges/schools of pharmacy to prepare student pharmacists/residents for academic careers. Methods Through the American Association of Colleges of Pharmac (AACP) Section of Pharmacy Practice, the Student Resident Engagement Task Force (SRETF) collated teaching materials used by colleges/schools of pharmacy from a previously reported national survey. The SRETF developed a toolkit for student pharmacists/residents interested in academic pharmacy. Results Eighteen institutions provided materials; five provided materials describing didactic coursework; over fifteen provided materials for an academia-focused Advanced Pharmacy Practice Experiences (APPE), while one provided materials for an APPE teaching-research elective. SRETF members created a syllabus template and sample lesson plan by integrating submitted resources. Submissions still needed to complete the toolkit include examples of curricular tracks and certificate programs. Discussion and conclusions Pharmacy faculty vacancies still exist in pharmacy education. Engaging student pharmacists/residents about academia pillars of teaching, scholarship and service is critical for the future success of the academy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer.
- Author
-
Jahid, Sohail, Ortega, Jose A., Vuong, Linh M., Acquistapace, Isabella Maria, Hachey, Stephanie J., Flesher, Jessica L., La Serra, Maria Antonietta, Brindani, Nicoletta, La Sala, Giuseppina, Manigrasso, Jacopo, Arencibia, Jose M., Bertozzi, Sine Mandrup, Summa, Maria, Bertorelli, Rosalia, Armirotti, Andrea, Jin, Rongsheng, Liu, Zheng, Chen, Chi-Fen, Edwards, Robert, and Hughes, Christopher C.W.
- Published
- 2022
- Full Text
- View/download PDF
9. Presynaptic mGlu7 receptors control GABA release in mouse hippocampus
- Author
-
Summa, Maria, Di Prisco, Silvia, Grilli, Massimo, Usai, Cesare, Marchi, Mario, and Pittaluga, Anna
- Subjects
- *
GLUTAMATE receptors , *SODIUM dodecyl sulfate , *POLYACRYLAMIDE gel electrophoresis , *PRESYNAPTIC receptors , *GABA transporters , *FORSKOLIN , *HIPPOCAMPUS physiology , *AMINOBUTYRIC acid , *CELL membranes , *LABORATORY mice - Abstract
Abstract: The functional role of presynaptic release-regulating metabotropic glutamate type 7 (mGlu7) receptors in hippocampal GABAergic terminals was investigated. Mouse hippocampal synaptosomes were preloaded with [3H]D-γ-aminobutyric acid ([3H]GABA) and then exposed in superfusion to 12 mM KCl. The K+-evoked [3H]GABA release was inhibited by the mGlu7 allosteric agonist N,N′-dibenzyhydryl-ethane-1,2-diamine dihydrochloride (AMN082, 0.001–10 μM), as well as by the group III mGlu receptor agonist l-(+)-2-amino-4-phosphonobutyric acid [(l)-AP4, 0.01–1 mM]. The mGlu8 receptor agonist (S)-3,4-dicarboxyphenylglycine [(S)-3,4-DCPG, 10–100 nM] was ineffective. AMN082 and (l)-AP4-induced effects were recovered by the mGlu7 negative allosteric modulator (NAM) 6-(4-methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[4,5-c]pyridin-4(5H)-one hydrochloride (MMPIP). AMN082 also inhibited in a MMPIP-sensitive manner the K+-evoked release of endogenous GABA. AMN082 and the adenylyl cyclase (AC) inhibitor MDL-12,330A reduced [3H]GABA exocytosis in a 8-Br-cAMP-sensitive. AMN082-inhibitory effect was additive to that caused by (−)baclofen, but insensitive to the GABAB antagonist 3-[[(3,4-Dichlorophenyl)methyl]amino]propyl] diethoxymethyl) phosphinic acid (CGP52432). Conversely, (−)baclofen-induced inhibition of GABA exocytosis was insensitive to MMPIP. Finally, the forskolin-evoked [3H]GABA release was reduced by AMN082 or (−)baclofen but abolished when the two agonists were added concomitantly. Mouse hippocampal synaptosomal plasmamembranes posses mGlu7 receptor proteins; confocal microscopy analysis unveiled that mGlu7 proteins colocalize with syntaxin-1A (Stx-1A), with vesicular GABA transporter (VGAT)-proteins and with GABAB receptor subunit proteins. We propose that presynaptic inhibitory mGlu7 heteroreceptors, negatively coupled to AC-dependent intraterminal pathway, exist in mouse hippocampal GABA-containing terminals, where they colocalize, but do not functionally cross-talk, with GABAB autoreceptors. This article is part of a Special Issue entitled ‘Metabotropic Glutamate Receptors’. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
10. In vitro exposure to nicotine induces endocytosis of presynaptic AMPA receptors modulating dopamine release in rat nucleus accumbens nerve terminals
- Author
-
Grilli, Massimo, Summa, Maria, Salamone, Alessia, Olivero, Guendalina, Zappettini, Stefania, Di Prisco, Silvia, Feligioni, Marco, Usai, Cesare, Pittaluga, Anna, and Marchi, Mario
- Subjects
- *
ENDOCYTOSIS , *PHYSIOLOGICAL effects of nicotine , *IMMUNOCYTOCHEMISTRY , *NUCLEUS accumbens , *AMPA receptors , *DOPAMINE , *LABORATORY rats - Abstract
Abstract: Here we provide functional and immunocytochemical evidence supporting the presence on Nucleus Accumbens (NAc) dopaminergic terminals of cyclothiazide-sensitive, alfa-amino-3-hydroxy-5-methyl-4-isoxazolone propionate (AMPA) receptors, which activation causes Ca2+-dependent [3H]dopamine ([3H]DA) exocytosis. These AMPA receptors cross-talk with co-localized nicotinic receptors (nAChRs), as suggested by the finding that in vitro short-term pre-exposure of synaptosomes to 30 μM nicotine caused a significant reduction of both the 30 μM nicotine and the 100 μM AMPA-evoked [3H]DA overflow. Entrapping pep2-SVKI, a peptide known to compete for the binding of GluA2 subunit to scaffolding proteins involved in AMPA receptor endocytosis, in NAC synaptosomes prevented the nicotine-induced reduction of AMPA-mediated [3H]DA exocytosis, while pep2-SVKE, used as negative control, was inefficacious. Immunocytochemical studies showed that a significant percentage of NAc terminals were dopaminergic and that most of these terminals also posses GluA2 receptor subunits. Western blot analysis of GluA2 immunoreactivity showed that presynaptic GluA2 proteins in NAc terminals were reduced in nicotine-pretreated synaptosomes when compared to the control. The nACh-AMPA receptor–receptor interaction was not limited to dopaminergic terminals since nicotine pre-exposure also affected the presynaptic AMPA receptors controlling hippocampal noradrenaline release, but not the presynaptic AMPA receptors controlling GABA and acetylcholine release. These observations could be relevant to the comprehension of the molecular mechanisms at the basis of nicotine rewarding. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
11. Hippocampal AMPA autoreceptors positively coupled to NMDA autoreceptors traffic in a constitutive manner and undergo adaptative changes following enriched environment training
- Author
-
Summa, Maria, Di Prisco, Silvia, Grilli, Massimo, Marchi, Mario, and Pittaluga, Anna
- Subjects
- *
HIPPOCAMPUS (Brain) , *PROPIONIC acid , *AUTORECEPTORS , *METHYL aspartate , *GLUTAMIC acid , *CENTRAL nervous system , *PROTEIN-protein interactions , *POLYACRYLAMIDE gel electrophoresis - Abstract
Abstract: α-Amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) autoreceptors exist on glutamate hippocampal terminals. Aimed at investigating whether these autoreceptors traffic constitutively, (S)AMPA-evoked [3H]D-ASP release from synaptosomes enriched with peptides that impede the interaction of GluA2 subunits with cytosolic proteins involved in receptor movements [namely Glutamate Receptor-Interacting Protein (GRIP), Protein Interacting with C kinase 1 (PICK1), N-ethyl-maleimide-Sensitive Fusion protein NSF proteins] was monitored. (S)AMPA alone had no effect on the spontaneous release of [3H]D-ASP from control synaptosomes, but became efficacious in the presence of cyclothiazide or when preventing GluA2/GRIP/PICK1, but not GluA2/NSF, interaction. Hippocampal glutamatergic terminals also possess NMDA autoreceptors. 10 μM NMDA/1 μM glycine-induced [3H]D-ASP release was concentration-dependently increased by (S)AMPA. Cyclothiazide potentiated the 10 μM NMDA/1 μM glycine/50 μM (S)AMPA-induced [3H]D-ASP overflow, while NBQX halved and MK-801 abolished it, suggesting NMDA-AMPA autoreceptor cross-talk. Western Blot analysis of sub-synaptic fractions confirmed presynaptic GluN2B-GluA2/3 co-localization. Impeding GluA2/GRIP/PICK1 interaction facilitated the NMDA/glycine/(S)AMPA-induced release of [3H]D-ASP, while competing for GluA2/NSF interaction reduced it, indicating that NMDA receptor favours AMPA receptor insertion in synaptosomal plasmamembranes. Finally, rearing mice in enriched environment unveiled the (S)AMPA-induced release of [3H]D-ASP, but leaved unmodified that caused by NMDA/glycine. The NBQX-sensitive, 50 μM (S)AMPA-evoked release of [3H]D-ASP was insensitive to cyclothiazide and to peptide interfering with GluA2/GRIP/PICK1 interaction but was addictive to that caused by NMDA/glycine. Presynaptic GluA2/3 immunoreactivity in EE hippocampal terminals was increased, while GluN2B was unchanged. We conclude that hippocampal AMPA autoreceptors positively coupled to NMDA autoreceptors traffic in a constitutive manner and undergo functional up-regulation in EE animals. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
12. PFAS-free superhydrophobic chitosan coating for fabrics.
- Author
-
Tagliaro, Irene, Mariani, Massimiliano, Akbari, Raziyeh, Contardi, Marco, Summa, Maria, Saliu, Francesco, Nisticò, Roberto, and Antonini, Carlo
- Subjects
- *
CHITOSAN , *FLUOROALKYL compounds , *COATED textiles , *CONTACT angle , *POLYWATER , *OXYGEN consumption - Abstract
In view of health and environmental concerns, together with the upcoming restrictive regulations on per - and polyfluoroalkyl substances (PFAS), less impactful materials must be explored for the hydrophobization of surfaces. Polysaccharides, and especially chitosan, are being explored for their desirable properties of film formation and ease of modification. We present a PFAS-free chitosan superhydrophobic coating for textiles deposited through a solvent-free method. By contact angle analysis and drop impact, we observe that the coating imparts hydrophobicity to the fabrics, reaching superhydrophobicty (θ A = 151°, θ R = 136°) with increased amount of coating (from 1.6 g/cm2). This effect is obtained by the combination of chemical water repellency of the modified chitosan and the nano- and micro-roughness, assessed by SEM analysis. We perform a comprehensive study on the durability of the coatings, showing good results especially for acidic soaking where the hydrophobicity is maintained until the 8th cycle of washing. We assess the degradation of the coating by a TGA-IR investigation to define the compounds released with thermal degradation, and we confirm the coating's biodegradability by biochemical oxygen consumption. Finally, we demonstrate its biocompatibility on keratinocytes (HaCaT cell line) and fibroblasts (HFF-1 cell line), confirming that the coating is safe for human skin cells. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
- Author
-
Capurro, Valeria, Lanfranco, Massimiliano, Summa, Maria, Porceddu, Pier Francesca, Ciampoli, Mariasole, Margaroli, Natasha, Durando, Lucia, Garrone, Beatrice, Ombrato, Rosella, Tongiani, Serena, and Reggiani, Angelo
- Subjects
- *
GLYCOGEN synthase kinase , *SERINE/THREONINE kinases , *AMINO acid residues , *BIPOLAR disorder , *PROTEIN kinases , *HOSTILITY - Abstract
• The novel GSK-3β inhibitor AF3581 has remarkable stabilizing properties on mood cycling, in animal models of mood disorders. • AF3581 prevented experimentally induced anhedonia in mice(down phase) and reduced the established aberrant hostile behavior towards intruder following long lasting isolation (up phase). • The efficacy of AF3581 in each animal model was always comparable to that of fully effective doses of reference drugs used. • In view of the promising pharmacological properties, AF3581 could be the prototype of a novel class of therapeutics for Bipolar Disorders. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N-[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N-[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N -[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzymeand highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N -[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N -[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N -[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK-3β has been linked to several disease conditions. There is now large evidence on the role of GSK-3β in the pathophysiology of mood disturbances with special regard to bipolar disorders. In the present study we further investigated the role of GSK-3β in bipolar disorders by studying AF3581, the prototype of a novel class of ATP-competitive GSK-3β inhibitors having the common N -[(1- alkylpiperidin-4-yl) methyl]-1H-indazole-3-carboxamide scaffold. Based on previous studies, AF3581 inhibits GSK-3β in the nanomolar range on purified human enzyme and highly selective with respect to other kinases. Current study demonstrates that the compound has efficacy both in the chronic mild stress paradigm of depression (mimicking the down phase of bipolar disorder) and on mice aggressiveness in the resident intruder model (mimicking the up phase). These findings underline the importance of aberrant GSK-3β activity in the development/ maintenance of mood oscillation in this peculiar pathological condition. Moreover, the present work also suggests a therapeutic potential for selective GSK-3 β inhibitors in the management of bipolar disorders patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties.
- Author
-
Basagni, Filippo, Ortega, Jose A., Bertozzi, Sine M., Armirotti, Andrea, Summa, Maria, Bertorelli, Rosalia, Bartolini, Manuela, Mellor, Ian R., Bedeschi, Martina, Bottegoni, Giovanni, Lembo, Vittorio, Minarini, Anna, Cavalli, Andrea, and Rosini, Michela
- Subjects
- *
ALZHEIMER'S disease , *DONEPEZIL , *PHARMACOKINETICS , *KINASE inhibitors , *PLASMA stability , *DOUBLE bonds , *ACETYLCHOLINESTERASE inhibitors - Abstract
Neurodegenerative processes characterizing Alzheimer's disease (AD) are strictly related to the impairment of cholinergic and glutamatergic neurotransmitter systems which provoke synaptic loss. These experimental evidences still represent the foundation of the actual standard-of-care treatment for AD, albeit palliative, consisting on the coadministration of an acetylcholinesterase inhibitor and the NMDAR antagonist memantine. In looking for more effective treatments, we previously developed a series of galantamine-memantine hybrids where compound 1 (ARN14140) emerged with the best-balanced action toward the targets of interest paired to neuroprotective efficacy in a murine AD model. Unfortunately, it showed a suboptimal pharmacokinetic profile, which required intracerebroventricular administration for in vivo studies. In this work we designed and synthesized new hybrids with fewer rotatable bonds, which is related to higher brain exposure. Particularly, compound 2 , bearing a double bond in the tether, ameliorated the biological profile of compound 1 in in vitro studies, increasing cholinesterases inhibitory potencies and selective antagonism toward excitotoxic-related GluN1/2B NMDAR over beneficial GluN1/2A NMDAR. Furthermore, it showed increased plasma stability and comparable microsomal stability in vitro , paired with lower half-life and faster clearance in vivo. Remarkably, pharmacokinetic evaluations of compound 2 showed a promising increase in brain uptake in comparison to compound 1 , representing the starting point for further chemical optimizations. [Display omitted] • New more rigid galantamine-memantine hybrids of ARN14140 (1) were synthesized. • The pharmacokinetic profile of 1 improved by increasing structure rigidity. • Compound 2 promisingly improved plasma stability in vitro and brain penetration in vivo. • Stronger ChEs inhibition and GluN1/2B NMDAR selective antagonism were achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Controlled antiseptic/eosin release from chitosan-based hydrogel modified fibrous substrates.
- Author
-
Romano, Ilaria, Ayadi, Farouk, Rizzello, Loris, Summa, Maria, Bertorelli, Rosalia, Pompa, Pier Paolo, Brandi, Fernando, Bayer, Ilker S., and Athanassiou, Athanassia
- Subjects
- *
CONTROLLED release drugs , *ANTISEPTICS , *EOSIN , *CHITOSAN , *HYDROGELS , *FIBERS , *CELLULOSE - Abstract
Fibers of cellulose networks were stably coated with N -methacrylate glycol chitosan (MGC) shells using subsequent steps of dip coating and photo-curing. The photo-crosslinked MGC-coated cellulose networks preserved their fibrous structure. A model hydrophilic antiseptic solution containing eosin, chloroxylenol and propylene glycol was incorporated into the shells to study the drug release dynamics. Detailed drug release mechanism into phosphate buffered saline (PBS) solutions from coated and pristine fibers loaded with the antiseptic was investigated. The results show that the MGC-coated cellulose fibers enable the controlled gradual release of the drug for four days, as opposed to fast, instantaneous release from eosin coated pristine fibers. This release behavior was found to affect the antibacterial efficiency of the fibrous cellulose sheets significantly against Staphylococcus aureus and Candida albicans . In the case of the MGC–eosin functionalized system the antibacterial efficiency was as high as 85% and 90%, respectively, while for the eosin coated pristine cellulose system the efficiency was negative, indicating bacterial proliferation. Furthermore, the MGC–eosin system was shown to be efficacious in a model of wound healing in mice, reducing the levels of various pro-inflammatory cytokines that modulate early inflammatory phase responses. The results demonstrate good potential of these coated fibers for wound dressing and healing applications. Due to its easy application on common passive commercial fibrous dressings such as gauzes and cotton fibers, the method can render them active dressings in a cost effective way. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice.
- Author
-
Di Prisco, Silvia, Merega, Elisa, Milanese, Marco, Summa, Maria, Casazza, Simona, Raffaghello, Lizzia, Pistoia, Vito, Uccelli, Antonio, and Pittaluga, Anna
- Subjects
- *
CCL5 (Chemokine) , *GLUTAMATE receptors , *CENTRAL nervous system , *SYNAPSES , *NEUROLOGICAL disorders , *ENCEPHALOMYELITIS , *LABORATORY mice - Abstract
Abstract: We investigated the CCL5-glutamate interaction in the cortex and in the spinal cord from mice with Experimental Autoimmune Encephalomyelitis (EAE) at 13 and 21/30 days post immunization (d.p.i.), representing the onset and the peak of the disease, respectively. An early reduction of the KCl-evoked glutamate release was observed in cortical terminals from EAE mice at 13 d.p.i., persisting until 21/30 d.p.i. A concomitant reduction of the depolarization-evoked cyclic adenosine monophosphate (cAMP), but not of the inositol 1,4,5-trisphosphate (IP3) cortical production also occurred at 13 d.p.i, that still was detectable at the acute stage of disease (21 dp.i.). Inasmuch, the CCL5-mediated inhibition of glutamate exocytosis observed in control mice turned to facilitation in EAE mouse cortex at 13 d.p.i., then becoming undetectable at 21/30 d.p.i. Differently, glutamate exocytosis, as well as IP3 and cAMP productions were unaltered in spinal cord synaptosomes from EAE mice at 13 d.p.i., but significantly increased at 21/30 d.p.i., while the presynaptic CCL5-mediated facilitation of glutamate exocytosis observed in control mice remained unchanged. In both CNS regions, the presynaptic defects were parallelled by increased CCL5 availability. Inasmuch, the presynaptic defects so far described in EAE mice were reminiscent of the effects acute CCL5 exerts in control conditions. Based on these observations we propose that increased CCL5 bioavailability could have a role in determining the abovedescribed impaired presynaptic impairments in both CNS regions. These presynaptic defects could be relevant to the onset of early cognitive impairments and acute neuroinflammation and demyelinating processes observed in multiple sclerosis patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
17. Natural Plasmodium infections in Brazilian wild monkeys: Reservoirs for human infections?
- Author
-
de Castro Duarte, Ana Maria Ribeiro, Malafronte, Rosely dos Santos, Cerutti, Crispim, Curado, Izilda, de Paiva, Byanca Regina, Maeda, Adriana Yurika, Yamasaki, Tasciane, Summa, Maria Eugênia Laurito, Neves, Dafne do Valle Dutra de Andrade, de Oliveira, Salma Gomes, and Gomes, Almério de Castro
- Subjects
- *
INFECTION , *MONKEYS , *PLASMODIUM , *MICROSCOPY - Abstract
Abstract: Four hundred and forty-eight samples of total blood from wild monkeys living in areas where human autochthonous malaria cases have been reported were screened for the presence of Plasmodium using microscopy and PCR analysis. Samples came from the following distinct ecological areas of Brazil: Atlantic forest (N =140), semideciduous Atlantic forest (N =257) and Cerrado (a savannah-like habitat) (N =51). Thick and thin blood smears of each specimen were examined and Plasmodium infection was screened by multiplex polymerase chain reaction (multiplex PCR). The frequency of Plasmodium infections detected by PCR in Alouatta guariba clamitans in the São Paulo Atlantic forest was 11.3% or 8/71 (5.6% for Plasmodium malariae and 5.6% for Plasmodium vivax) and one specimen was positive for Plasmodium falciparum (1.4%); Callithrix sp. (N =30) and Cebus apella (N =39) specimens were negative by PCR tests. Microscopy analysis was negative for all specimens from the Atlantic forest. The positivity rate for Alouatta caraya from semideciduous Atlantic forest was 6.8% (16/235) in the PCR tests (5.5, 0.8 and 0.4% for P. malariae, P. falciparum and P. vivax, respectively), while C. apella specimens were negative. Parasitological examination of the samples using thick smears revealed Plasmodium sp. infections in only seven specimens, which had few parasites (3.0%). Monkeys from the Cerrado (a savannah-like habitat) (42 specimens of A. caraya, 5 of Callithrix jacchus and 4 of C. apella) were negative in both tests. The parasitological prevalence of P. vivax and P. malariae in wild monkeys from Atlantic forest and semideciduous Atlantic forest and the finding of a positive result for P. falciparum in Alouatta from both types of forest support the hypothesis that monkeys belonging to this genus could be a potential reservoir. Furthermore, these findings raise the question of the relationship between simian and autochthonous human malaria in extra-Amazonian regions. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.